RNXT News and Press, RenovoRx Inc. From 04/18/24

RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that, in light of its recent successful fundraising ac...

Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers important data to potentially assist in optimization of TAMP therapy RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical compa...

With $17.2 million in gross proceeds raised since the beginning of 2024, RenovoRx has sufficient funding to advance pivotal Phase III clinical trial and expand development pipeline into additional cancer indications RenovoRx, Inc . (“RenovoRx” or the “...

2024-04-08 13:52:57 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips RenovoRx (NASDAQ: RNXT ) just reported results for the fourth quarter of 2023. RenovoRx reported earnings per share of -30 cents. This met the analyst estimate for EPS of ...

2024-04-08 08:45:51 ET More on RenovoRx RenovoRx closes $6.1M private placement Seeking Alpha’s Quant Rating on RenovoRx Read the full article on Seeking Alpha For further details see: RenovoRx to raise $11.1 million in a private placement; shares ...

Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and towards completion of the trial Financing also enables the expansion of RenovoRxȁ...

RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, RenovoRx’s Chief Executive ...

Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...

2024-03-14 10:00:17 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...